Xcell Biosciences Strengthens Cell and Gene Therapy Collaboration With Labcorp
Longstanding partnership deepens with new financing, beta access to clinical manufacturing instruments, and AACR data presentations
Xcellbio has developed the AVATAR incubator system for cell therapy research and development. Its latest platform, the AVATAR Foundry system, is a cGMP cell therapy manufacturing platform that delivers novel capabilities for improving the potency of cell therapies. These capabilities are especially important for cell therapies targeting solid tumors, which are frequently met with challenges in overcoming the harsh immunosuppressive tumor microenvironment (TME) to achieve durable potency at the target tumor site. The AVATAR and AVATAR Foundry systems offer small-scale research and process development as well as scale-up manufacturing platforms for metabolically reprogramming therapeutic cells to improve their potency and persistence in the TME.
“We have worked closely with the Xcellbio team for years and have been continually impressed by their dedication to improving the development and manufacture of cell and gene therapies,” said
Through the expanded collaboration, Labcorp’s preclinical oncology site in
“We are proud to be a trusted partner for
Poster Presentations at AACR
Along with scientific collaborators at
Poster #3908: Generation of new oncology cell models through long-term acclimation under hypoxic and hyperbaric culture conditions
Presenter:
Summary: In this poster, scientists will show that long-term acclimation of conventional tumor cell lines to conditions reflective of the TME alters their phenotype and gene expression profiles.
Poster #6334: Metabolic reprogramming enhances expansion and potency of CAR-T cells
Presenter:
Summary: This presentation will illustrate how manufacturing CD19 CAR T cells in optimized environmental conditions can enhance their expansion potential and potency, as measured with an in vitro tumor killing assay.
About
Xcellbio is driven by its mission to enhance the performance and safety of cell and gene-based therapies through the design and development of revolutionary technology platforms. The company’s commercial instruments and AI-driven software allow researchers to discover novel insights into immune and tumor biology and enable the translation of these insights at patient scale through the development of its pioneering cGMP cell therapy manufacturing platform. Based in
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20240401023455/en/
Media
For Xcellbio
suzanne@bioscribe.com
For
media@labcorp.com
Source: